Overview

A Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients

Status:
Completed

Trial end date:
2010-08-01

Target enrollment:

Participant gender:

Summary

The primary objective of the clinical study is to evaluate the efficacy and safety for Mikelan LA eye drops 2% (once per day) of intra-ocular pressure decreased.

Phase:

Phase 4

Details

Lead Sponsor:

Taiwan Otsuka Pharm. Co., Ltd

Treatments:

Carteolol
Latanoprost
Ophthalmic Solutions
Timolol